This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Q4 Scorecard & Analyst Reports for Pfizer, Boeing & Goldman Sachs
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Boeing (BA), Pfizer (PFE) and Goldman Sachs (GS).
Model N (MODN) Q1 Loss Narrower than Expected, Guides Well
by Zacks Equity Research
Model N, Inc. (MODN) reported a loss (excluding stock based compensation) of 21 cents per share in first-quarter 2017, which was narrower than the Zacks Consensus Estimate.
ARIAD Files for EU Approval of Lung Cancer Drug Brigatinib
by Zacks Equity Research
ARIAD Pharmaceuticals, Inc. (ARIA) announced the submission of a Marketing Authorisation Application (MAA) for its experimental ALK inhibitor, brigatinib, with the European Medicines Agency (EMA).
Agilent (A) Announces Expanded Use of Diagnostic Assay (revised)
by Zacks Equity Research
Agilent Technologies (A) recently announced the expanded use of its diagnostic assay, Dako PD-L1 IHC 22C3 pharmDx.
Q4 Earnings Faring Well for Pharma ETFs
by Sweta Killa
Despite the fact that the industry primes posted mixed results, the stocks witnessed smooth trading following their results.
Drug Stocks Reporting Earnings on Feb 7: GILD, MNK & More
by Zacks Equity Research
Earnings growth turned positive in the last quarter and things are surely looking up as we stand in the middle of the earnings season.
Portola, HealthCare Royalty Partners Ink $150 Million Deal
by Zacks Equity Research
Portola (PTLA) announced that it has signed a royalty agreement with HealthCare Royalty Partners (HCR) for $150 million.
Merck???s Keytruda Gets Priority Review for Bladder Cancer
by Zacks Equity Research
Merck & Co., Inc.???s (MRK) two supplemental Biologics License Applications (sBLA) for its anti-PD-1 therapy, Keytruda, have been accepted under priority review by the FDA.
Dow 30 Stock Roundup: Apple, Intel, Exxon Beat; Merck, Pfizer, Chevron Miss on Revenues
by Swarup Gupta
The Dow suffered losses over the week as optimism over Trump's election gave way to apprehension over his actions as President.
Pharma Stock Roundup: Pfizer, Merck, LLY Report Results, Teva Hit by Copaxone Ruling
by Arpita Dutt
Key highlights this week include a court ruling in the Copaxone patent infringement lawsuit and earnings results from companies like Pfizer (PFE).
Agilent (A) Announces Expanded Use of Diagnostic Assay
by Zacks Equity Research
Agilent Technologies (A) recently announced the expanded use of its diagnostic assay, Dako PD-L1 IHC 28-8 22C3 pharmDx. This marks the company's effort to expand in the growing companion diagnostics market.
Merck (MRK) Tops Q4 Earnings; Pharmaceutical Sales Down
by Zacks Equity Research
Merck & Co., Inc. (MRK) reported fourth-quarter 2016 earnings of 89 cents per share, which beat the Zacks Consensus Estimate of 88 cents by a penny.
Drug Stocks to Report Q4 Earnings on Feb 2: MRK & AMGN
by Zacks Equity Research
How will these two drug stocks, MRK & AMGN, which are both scheduled to report Q4 results on Feb 2, fare this earnings season?
Merck Keytruda Gets EU Approval for First-Line Lung Cancer
by Zacks Equity Research
Merck & Co., Inc. (MRK) announced that its anti-PD-1 therapy Keytruda has been approved by the European Commission for the first-line treatment of adult patients with metastatic non-small cell lung cancer.
SanofiRegeneron Sarilumab Approved in Canada for Arthritis
by Zacks Equity Research
Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced that their pipeline candidate, sarilumab, has been approved in Canada for the treatment of adult patients with moderate-to-severely active rheumatoid arthritis (RA).
Trade War Concerns Coming Home to Roost
by Mark Vickery
It hadn't been priced in at all during the Trump Rally, but now fears of a trade war with China and Mexico are being actualized.
Pfizer (PFE) Q4 Earnings Lag, Sales Top; '17 Sales View Soft
by Kinjel Shah
Pfizer, Inc. (PFE) missed earnings estimates in the fourth quarter.
Pfizer (PFE) Misses on Q4 Earnings; Tops Sales Estimate
by Zacks Equity Research
PFE missed fourth quarter earnings which came in at 47 cents while our consensus called for EPS of 50 cents.
Pfizer (PFE) Gets Positive CHMP Opinion for Arthritis Drug
by Zacks Equity Research
Pfizer Inc. (PFE) announced that Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion for the company's marketing authorisation application (MAA) for its rheumatoid arthritis (RA) drug, Xeljanz.
Drug Stocks Reporting Q4 Earnings on Jan 31: LLY and PFE
by Zacks Equity Research
Two pharma giants - Pfizer and Lilly - are set to report fourth-quarter results on Jan 31. Let's see how things are shaping up for this quarter.
Pfizer (PFE) C. Difficile Vaccine Positive in Phase II Study
by Zacks Equity Research
Pfizer Inc. (PFE) announced positive top-line results from a phase II study on its investigational vaccine candidate, PF-06425090, for the prevention of clostridium difficile infection.
Merck (MRK): Stock to Gain on Likely Earnings Beat in Q4?
by Zacks Equity Research
We expect pharma heavyweight Merck & Co., Inc. (MRK) to beat expectations when it reports fourth-quarter 2016 and full-year earnings results on Feb 2.
Will Amgen (AMGN) Keep the Earnings Streak Alive in Q4?
by Zacks Equity Research
We expect biotech major Amgen Inc. (AMGN) to beat expectations when it reports fourth-quarter 2016 and full-year results on Feb 2.
Pharma Stock Roundup: J&J to Buy Actelion, Bristol-Myers' 4Q Results Disappoint
by Arpita Dutt
Key highlights this week include earnings reports from companies like Bristol-Myers (BMY) as well as the J&J-Actelion deal.
Earnings Growth Returns, Will it Continue?
by Sheraz Mian
Corporate earnings have started growing again.